On Wednesday, March 20, the Federal Circuit ruled that “discovery is not allowed in inter partes patent reexaminations.” The finding denies a bid by Cordis Corp. to subpoena Abbott Laboratories for discovery in an inter partes proceeding before the U.S. Patent and Trademark Office (USPTO). The decision noted that the Patent Act allows district courts to issue subpoenas in “any contested case” at the USPTO. The Federal Circuit found that reexaminations are not “contested.” Finnegan represented Abbott in this matter.
Award/Ranking
Best Lawyers in Germany Recognizes Dr. Dr. Jochen Herr in Recent Rankings
July 16, 2026
Commentary
Patent Strategy Could Shape Financing, Valuation and Risk in Offshore Energy Projects
June 30, 2026
Award/Ranking
Finnegan’s European Practices and Attorneys Highlighted in 2026 Managing IP Rankings
June 25, 2026
Press Release
BMW Obtains Preliminary Injunction Against Zync; Federal Court Orders Zync to Halt ITC Trade Secret
June 23, 2026
Award/Ranking
Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers
June 22, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.